NCT07223541
Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT07223541
Title Cemiplimab or Cemiplimab and Fianlimab After Stereotactic Body Radiotherapy in Clear Cell Renal Cell Carcinoma (LAG-BOOST)
Acronym LAG-BOOST
Recruitment Not yet recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors University of Oklahoma
Indications
Therapies
Age Groups: adult | senior
Covered Countries USA


No variant requirements are available.